Compare FMC Corp (FMC) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs Novavax Inc — how do they compare? FMC Corp trades at $8.89 (market cap $1.41B), while Novavax Inc trades at $11 (market cap $1.85B). The key difference: Novavax Inc is the larger of the two by market cap, and FMC Corp pays a 3.52% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FMC Corp for 68 Days and Novavax Inc for 59 Days on average.
| FMC | NVAX | |
|---|---|---|
Market Cap | $1.41B | $1.85B |
Volume | 4,507,459 | 8,362,562 |
Sector | Basic Materials | Health |
52-Week High | $30.63 | $12.56 |
52-Week Low | $8.44 | $6.22 |
Typical Hold Time | 68 Days | 59 Days |
Enterprise Value | $5.22B | $1.43B |
Dividend Yield | 3.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC trades at $8.92, down 1.22% on the day, with a bearish technical signal and negative profitability metrics including a net income margin of -84.83% and ROE of -91.47% for 2025. Recent news highlights regulatory progress with rimisoxafen in Brazil and a minority equity investment from Tessenderlo Group. Cash flow trends show volatility, with 2025 net cash flow positive at $227.20M but driven by financing activities as operating cash flow was negative.
The outlook is challenged by significant losses and high debt, though analyst consensus suggests upside with a $14.60 price target. Key risks include sustained negative margins, industry cyclicality, and execution of deleveraging plans. The stock presents a high-risk opportunity contingent on operational turnaround and debt reduction success.
Novavax (NVAX) trades at $11.01, down 2.74% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported strong revenue of $1.12B in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Recent news highlights the company's pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in major markets.
Investment outlook remains speculative with analyst consensus heavily favoring Buy ratings (73.92%) but fundamental risks persist including negative cash flow trends and high debt levels. The stock offers potential upside from partnership expansions but faces significant execution and competitive risks in the biopharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
